Wellah Marie San Buenaventura
Gerontology · Atwater, CANPI 1548806953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,083 and has fallen 89.3% since, to $116 in 2025.
Across 81 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$550
- Ultragenyx Pharmaceutical Inc.$168
- Novo Nordisk$151
- Neurocrine Biosciences, Inc.$135
- AstraZeneca$135
- Lilly USA, LLC$109
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 8 | $550 |
| Ultragenyx Pharmaceutical Inc. | 7 | $168 |
| Novo Nordisk | 4 | $151 |
| Neurocrine Biosciences, Inc. | 1 | $135 |
| AstraZeneca | 2 | $135 |
| Lilly USA, LLC | 6 | $109 |
| Boehringer Ingelheim | 2 | $104 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $86 |
| Philips North America LLC | 5 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Johnson & Johnson | 4 | $66 |
| Sanofi Pasteur Inc. | 3 | $61 |
| Baxter Healthcare | 2 | $57 |
| Shield Therapeutics Inc | 3 | $56 |
| Exact Sciences | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Novartis | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| AbbVie | 2 | $33 |
| Edwards Lifesciences | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Amarin Pharma, Inc. | 2 | $25 |
| Qiagen, LLC | 1 | $23 |
| Amgen | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Pfizer | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
| Seqirus USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,293 in reported general payments places this provider in the 85th percentile of 348 gerontology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $61,141 |
| OzempicSemaglutide | 41 | $40,685 |
| XareltoRivaroxaban | 21 | $24,763 |
| JanuviaSitagliptin Phosphate | 14 | $21,740 |
| JardianceEmpagliflozin | 18 | $17,371 |
| TrulicityDulaglutide | 14 | $16,798 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $15,829 |
| MounjaroTirzepatide | 11 | $13,120 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,094 |
| Famotidine | 28 | $3,951 |
| Gabapentin | 92 | $3,174 |
| Atorvastatin Calcium | 329 | $3,065 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $2,610 |
| Levothyroxine Sodium | 173 | $2,309 |
| Simvastatin | 139 | $1,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $61,14141 claims |
| Novo NordiskOzempic | $151 | $40,68541 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $109 | $29,91725 claims |
| Johnson & JohnsonXarelto | $66 | $24,76321 claims |
| MerckJanuvia | $15 | $21,74014 claims |
| Boehringer IngelheimJardiance | $104 | $17,37118 claims |
| GSKTrelegy Ellipta | $550 | $15,82918 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $42 | $6,09412 claims |
| AbbVieSynthroid | $33 | $1,20015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 348 gerontology providers in California.
Other gerontology in Atwater
- Lovely IsraelSanta Monica$95K
- Leslie TarlowLos Angeles$58K
- Christine PartamianPorter Ranch$41K
- Elsa Pineda-FloresLos Angeles$24K
- Maria MottaDuarte$23K
- Daniel ChiuOrange$17K
- Katiaryna KulinichChula Vista$15K
- Nataliya OsorioRiverside$13K
- Anne Marie de Joya ReeveDuarte$11K
- Wendy AlmonteLemoore$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.